[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100407982":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) who initiate treatment for the first time with brigatinib in a routine clinical practical setting will be observed prospectively for up to 24 month-surveillance period.",[13],"Other: No Intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No Intervention","This is a non-interventional study.",[9],[21],{"name":22,"affiliation":5,"role":23},"Study Director","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Pusan National University Hospital","RECRUITING","Busan","49241","South Korea",{"type":38,"coordinates":39},"Point",[40,41],129.03004,35.10168,{"lat":41,"lon":40},{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100407982","a-study-of-usage-of-brigatinib-in-the-treatment-of-adult-participants-for-approved-indications-in-south-korea-100407982",false,"NCT04592523","A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea","Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea","Inclusion Criteria:\n\n1. With ALK-positive advanced or metastatic NSCLC.\n2. Who initiate brigatinib for the first time.\n\nExclusion Criteria:\n\n1. Treated with brigatinib outside of the locally approved label in Korea.\n2. Whom brigatinib is contraindicated as per product label.\n3. Participating in other clinical trials of NSCLC treatment.","ALL","19 Years",{"count":55,"type":56},257,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.",[60,61],"Carcinoma, Non-Small-Cell Lung","Anaplastic Lymphoma Kinase",[63],"Drug Therapy","2025-12-17",{"date":66,"type":67},"2025-12-24","ACTUAL",{"date":69,"type":67},"2019-09-05",{"date":71,"type":56},"2026-08-26",{"name":5,"class":6},1]